Recombinant leukocyte A interferon in B-cell XXXX : in vivo effects on autologous antitumor immunity.

@entity1 @entity137 @entity308 @entity353 @entity5 @entity448 @entity1072 @entity683
Eight previously treated and four untreated @entity1 with @entity1072 ( @entity1072 ) received 20 X 10(6) U/m2 recombinant leukocyte interferon clone A (rIFN-alpha A) intramuscularly three times a week for 8 weeks. None of the eight @entity1 who had received prior chemotherapy exhibited objective evidence of @entity5 regression. Two of the four previously untreated @entity1 responded with transient (90%) decreases in absolute lymphocyte counts lasting for 2 and 7 months. @entity137 was moderate, with all @entity1 experiencing @entity683 requiring a 50% dose reduction. Half of the @entity1 exhibited @entity448 , @entity353 , and a drop in performance status. The two responders had normal serum immunoglobulin levels prior to treatment, whereas 80% of non-responders had depressed levels. Treatment with rIFN-alpha A was associated with a @entity308 of nonspecific and specific humoral immunity in assays employing cryopreserved autologous pretherapy @entity1072 cells. No consistent effects were demonstrable in cytolytic assays with purified peripheral blood T cells as effector cells, including one that utilized autologous @entity1072 target cells. rIFN-alpha A has limited antitumor activity in @entity1072 which is restricted to untreated @entity1 with an early stage of disease. With the assays employed it was not possible to demonstrate that rIFN-alpha A could augment autologous antitumor immunity.
